In the 1980s, Bayer's Cutter Biological division continued selling Factor VIII blood-clotting concentrate — known to be contaminated with HIV — to markets in Asia and Latin America even after introducing a safer heat-treated version in the US. Internal documents showed the company made a financial decision to sell old stock rather than destroy it. Thousands of hemophiliacs were infected with HIV. Bayer eventually settled lawsuits for $600 million.